Natera, Inc. (NASDAQ:NTRA) Q4 2023 Results Conference Call February 28, 2024 4:30 PM ET

Company Participants

Michael Brophy - Chief Financial Officer

Steve Chapman - Chief Executive Officer

Solomon Moshkevich - President, Clinical Diagnostics

Alexey Aleshin - General Manager of Oncology & Chief Medical Officer

John Fesco - President & Chief Business Officer

Conference Call Participants

Subbu Nambi - Guggenheim

Puneet Souda - Leerink Partners

David Westenberg - Piper Sander

Tejas Savant - Morgan Stanley

Doug Schenkel - Wolfe Research

Matt Sykes - Goldman Sachs

Operator

Ladies and gentlemen, thank you for standing by. My name is Desiree, and I will be your conference operator today. At this time, I would like to welcome everyone to the Natera Inc. Fourth Quarter 2023 Earnings Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. [Operator Instructions]

I would now like to turn the conference over to Michael Brophy, Chief Financial Officer. Please go ahead.

Michael Brophy

Thanks, operator. Good afternoon. Thank you for joining our conference call to discuss the results of our fourth quarter of 2023. On the line, I'm joined by Steve Chapman, our CEO; Solomon Moshkevich, President, Clinical Diagnostics; and Alexey Aleshin, General Manager of Oncology and Chief Medical Officer. John Fesco, President and Chief Business Officer is also on the line and will be available for Q&A.

Today's conference call is being broadcast live via webcast. We will be referring to a slide presentation that has been posted to investor.natera.com. A replay of the call will also be posted to our IR site as soon as it's available.

Starting on Slide 2, during the course of this conference call, we will make forward-looking statements regarding future events and our anticipated future performance such as our operational and financial outlook and projections, our assumptions for that outlook, market size partnerships, clinical studies and expected results, opportunities and strategies and expectations for various current and future products including product capabilities, expected release dates, reimbursement coverage and related effects on our financial and operating results.

We caution you that such statements reflect our best judgment based on factors currently known to us and that actual events or results could differ materially. Please refer to the documents we file from time to time with the SEC, including our most recent Form 10-K or 10-Q and the Form 8-K filed with today's press release. Those documents identify important risks and other factors that may cause our actual results to differ materially from those contained or suggested by the forward-looking statements.